Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
United Health Products, Inc. is a U.S.-based medical device company focused on the development, manufacture, and commercialization of hemostatic products used to control bleeding. The company operates primarily within the medical devices and surgical consumables industries, serving healthcare providers that require rapid bleeding control solutions in surgical, emergency, and wound-care settings. Its activities are centered on regulated healthcare markets rather than consumer healthcare.
The company’s core product is HemoStyp, a proprietary hemostatic gauze designed to accelerate clotting and reduce bleeding without introducing chemical agents or animal-derived components. Revenue generation has historically been tied to product sales, distribution agreements, and efforts to expand clinical adoption. United Health Products was incorporated in 2002 and initially focused on wound-care technologies before narrowing its strategy around hemostatic solutions as its primary commercial focus.
Business Operations
United Health Products operates as a single-reporting-segment company, with substantially all operations related to the development and commercialization of HemoStyp and related hemostatic products. The company generates revenue through direct sales and distributor relationships, primarily targeting hospitals, surgical centers, and healthcare providers. As of publicly available disclosures, commercial traction has been limited, and operating results have reflected early-stage commercialization dynamics.
Operations are primarily domestic, with manufacturing and product oversight conducted through third-party manufacturers and suppliers rather than vertically integrated facilities. The company controls intellectual property related to its hemostatic technology and relies on regulatory clearances, including U.S. FDA clearance, to market its products. Public filings do not indicate material joint ventures, and the company does not report significant operating subsidiaries.
Strategic Position & Investments
Strategically, United Health Products has emphasized expanding clinical validation and market awareness of HemoStyp as a differentiating hemostatic solution that does not rely on biologics or synthetic clotting agents. Growth initiatives have focused on penetrating surgical, dental, and emergency care markets where rapid bleeding control is critical. The company has also highlighted potential applications in military, trauma, and first-responder environments.
Public disclosures indicate no material acquisitions or diversified investment portfolio. The company’s strategy is primarily organic, centered on product adoption, distribution expansion, and regulatory positioning. Data inconclusive based on available public sources regarding material investments in emerging technologies beyond its existing hemostatic platform.
Geographic Footprint
United Health Products is headquartered in the United States and derives the majority of its operational focus and revenue from the North American market. Regulatory approvals and commercialization efforts have been primarily U.S.-centric, reflecting the company’s size and resource allocation.
International activity has been referenced in the context of potential distribution opportunities, but public filings do not confirm material or sustained revenue contributions from Europe, Asia, or other global regions. Data inconclusive based on available public sources regarding the scale of international operations or long-term overseas investments.
Leadership & Governance
United Health Products is led by an executive team with experience in healthcare, medical devices, and corporate management. The company is governed by a board of directors responsible for oversight, strategy, and compliance with public company reporting obligations. Leadership communications emphasize disciplined commercialization, regulatory compliance, and long-term value creation through product adoption.
Key executives include:
- Mitchell J. Felder – Chief Executive Officer
- Robert W. Schmider – Chief Financial Officer
- Ira L. Shafran – Chairman of the Board
The leadership philosophy, as reflected in public filings and statements, centers on advancing a focused product portfolio, maintaining capital discipline, and pursuing partnerships that can accelerate market penetration while managing operational risk.